India's COVID-19 tally crosses 96.08 lakh with 36,652 new cases; toll nears 1.40 lakh

-

New Delhi: India's COVID-19 caseload climbed to 96.08 lakh on Saturday after 36,652 fresh infections were registered in a day, said the health ministry.

With more than 90.58 lakh patients being cured, the national recovery rate was pushed to 94.28 percent.

The total number of confirmed cases mounted to 96,08,211 and the toll reached 1,39,700 with the novel coronavirus claiming 512 lives in a span of 24 hours, the data updated at 8 am showed.

The COVID-19 case fatality rate was recorded at 1.45 percent.

There are currently 4,09,689 active cases of coronavirus infection in the country, which comprise 4.26 percent of the total caseload, the health ministry said.

According to the Indian Council of Medical Research (ICMR), a cumulative total of 14,58,85,512 samples have been tested up to 4 December. At least 11,57,763 samples were tested on Friday alone.

India's COVID-19 tally had crossed the 20-lakh mark on 7 August, 30 lakh on 23 August and 40 lakh on 5 September. It went past 50 lakh on 16 September, 60 lakh on 28 September, 70 lakh on 11 October, crossed 80 lakh on 29 October and 90 lakh on 2 0November.

The 512 new fatalities include 127 from Maharashtra, 73 from Delhi, 52 from West Bengal, 29 each from Uttar Pradesh and Kerala, 20 from Punjab, 19 from Haryana, 15 from Chhattisgarh and 13 from Karnataka.

A total of 1,39,700 deaths have been reported so far in the country including 47,599 from Maharashtra followed by 11,834 from Karnataka, 11,762 from Tamil Nadu, 9,497 from Delhi, 8,628 from West Bengal, 7,877 from Uttar Pradesh, 7,020 from Andhra Pradesh, 4,882 from Punjab and 4,049 from Gujarat.

The health ministry stressed that more than 70 percent of the deaths occurred due to comorbidities.

"Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation.



from Firstpost India Latest News https://ift.tt/3ojNUkO
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more